KRT88P and infection: Analysis of the hepatitis B markers showed that 25.7% (95%CI: 22.4-29.4%) of participants were non-reactive for anti-HBc and reactive for anti-HBs (vaccine marker), and none had an active infection at the time of sample collection (Table 2).